Cargando…

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study

INTRODUCTION: Evaluating overall survival in randomized controlled trials (RCTs) can often be confounded by bias introduced by treatment switching. SERAPHIN was a large RCT that evaluated the effects of long-term treatment with the endothelin receptor antagonist macitentan in patients with pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Scala, Lilla, Bacchi, Marisa, Bayer, Bjørn, Turricchia, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402487/ https://www.ncbi.nlm.nih.gov/pubmed/35917059 http://dx.doi.org/10.1007/s12325-022-02253-8

Ejemplares similares

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
por: Skaltsa, Konstantina, et al.
Publicado: (2016)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
por: Souza, Rogério, et al.
Publicado: (2018)

Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model()
por: Temple, I.P., et al.
Publicado: (2014)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension
por: Kim, Kyung-Hee, et al.
Publicado: (2018)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
por: Latimer, Nicholas R., et al.
Publicado: (2016)

Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
por: Li, Niuniu, et al.
Publicado: (2023)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing Macitentan
por: Murphy, Gerard, et al.
Publicado: (2022)

Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qin, Jinlv, et al.
Publicado: (2023)

Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　― Protocol of a Multicenter Randomized Control Trial ―
por: Akagi, Satoshi, et al.
Publicado: (2021)

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
por: Lattanzio, Mariangela, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

The use of Macitentan in Fontan circulation: a case report
por: Demetriades, Polyvios, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bh1unaftoaj1bob50fjd8740lp